Blood-derived cell-free DNA is a superior biomarker for noninvasive DNA methylation profiling in multiple myeloma.

作者信息

Heestermans Robbe, Olsen Catharina, Ameli Shervine, Succari Jana, Janssen Toon, De Brouwer Wouter, De Becker Ann, Vande Broek Isabelle, Bakkus Marleen, Schots Rik, De Bruyne Elke, Van Riet Ivan

机构信息

Translational Oncology Research Center, Team Hematology and Immunology, Vrije Universiteit Brussel, Brussels, Belgium.

Department of Hematology, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel, Brussels, Belgium.

出版信息

Blood Adv. 2025 Aug 26;9(16):4306-4310. doi: 10.1182/bloodadvances.2025016480.

DOI:10.1182/bloodadvances.2025016480

PMID:40561508

Abstract

摘要

相似文献

[1]

Blood-derived cell-free DNA is a superior biomarker for noninvasive DNA methylation profiling in multiple myeloma.

Blood Adv. 2025-8-26

[2]

Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review.

Clin Epigenetics. 2023-2-14

[3]

Noninvasive prognostication of hepatocellular carcinoma based on cell-free DNA methylation.

PLoS One. 2025-4-25

[4]

Blood-based DNA methylation as biomarker for breast cancer: a systematic review.

Clin Epigenetics. 2016-11-14

[5]

cfMethylPre: deep transfer learning enhances cancer detection based on circulating cell-free DNA methylation profiling.

Brief Bioinform. 2025-5-1

[6]

Colorectal Cancer Biomarker Identification via Joint DNA-Methylation and Transcriptomics Analysis Workflow.

Genes (Basel). 2025-5-23

[7]

Circulating cell-free DNA methylation profiles as noninvasive multiple sclerosis biomarkers: A proof-of-concept study.

medRxiv. 2025-2-20

[8]

Identification of Novel DNA Methylation Prognostic Biomarkers for AML With Normal Cytogenetics.

JCO Clin Cancer Inform. 2024-7

[9]

Single-molecule epiallelic profiling of DNA derived from routinely collected Pap specimens for noninvasive detection of ovarian cancer.

Clin Transl Med. 2024-8

[10]

Plasma cell free DNA methylation markers for hepatocellular carcinoma surveillance in patients with cirrhosis: a case control study.

BMC Gastroenterol. 2021-3-25

本文引用的文献

[1]

5-Hydroxymethylcytosine Profiles of cfDNA in Urine as Diagnostic, Differential Diagnosis and Prognostic Markers for Multiple Myeloma.

Cancer Med. 2024-12

[2]

Multiple myeloma: signaling pathways and targeted therapy.

Mol Biomed. 2024-7-4

[3]

Liquid Biopsies as Non-Invasive Tools for Mutation Profiling in Multiple Myeloma: Application Potential, Challenges, and Opportunities.

Int J Mol Sci. 2024-5-10

[4]

Author Correction: Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation.

Nat Cancer. 2023-11

[5]

Prognostic value of extracellular matrix gene mutations and expression in multiple myeloma.

Blood Cancer J. 2023-3-23

[6]

DNA methylation in circulating leukocytes is a novel biomarker in multiple myeloma.

Bone Marrow Transplant. 2023-3

[7]

Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma.

Clin Cancer Res. 2023-1-4

[8]

Liquid Biopsy-Derived DNA Sources as Tools for Comprehensive Mutation Profiling in Multiple Myeloma: A Comparative Study.

Cancers (Basel). 2022-10-7

[9]

Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?

Front Oncol. 2022-8-18

[10]

Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myeloma.

J Hematol Oncol. 2022-8-16

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

新学期，新优惠

Blood-derived cell-free DNA is a superior biomarker for noninvasive DNA methylation profiling in multiple myeloma.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

推荐工具

Suppr 超能文献

相似文献

本文引用的文献